WASHINGTON — A former senator told his ex-colleagues that, to grow investment and speed the progress of cures, the FDA must be more adaptive in its approval process, more transparent, and more collaborative.
Tom Coburn, MD, an Oklahoma Republican who retired from the Senate earlier this year, spoke at a Senate Committee on Commerce, Science and Transportation hearing on Tuesday. He and other witnesses discussed ways to increase investment in biomedical research, which committee leaders said has stagnated over the last few years.
